Abstract

Data on the feasibility of left bundle branch area pacing (LBBAP) and atrioventricular node (AVN) ablation in patients with pulmonary hypertension (PH) are limited. This study investigated the characteristics and outcomes of LBBAP and AVN ablation in patients with PH. This is a retrospective study of patients with PH and AF who underwent LBBAP and AVN ablation at the Cleveland Clinic between January 1, 2019 and August 1, 2022. Pre-procedural, post-procedural, and follow-up patient data were obtained. A total of 11 patients (mean age 74±10 years old, 100% female) with PH and AF who underwent concomitant LBBAP and AVN ablation were included. The etiology of PH was Group III PH in all patients (55% had COPD and 91% had restrictive lung disease), with the average pulmonary arterial systolic pressure (PASP) of 42 mmHg by echocardiogram, FEV1 of 61.9±17.4% predicted, and FVC of 59.9±7.8% predicted. Baseline ejection fraction was 57±10%, QRS duration was 96±20 ms. Concomitant LBBAP and AVN ablation was successful in all patients. Final implant characteristics included: QRS duration was 124±8 ms, left ventricular activation time was 73.7±5.4 ms; threshold 0.6±0.2 mV @ 0.4 ms and was 0.7±0.2 mV @ 0.4 ms on follow-up; impedance was 618±119 ohms and was 545±145 ohms on follow-up. Prior to the LBBAP and AVN ablation procedure, the average number of AF or heart failure (HF) hospitalizations 24 months prior to the procedure was 4.9±5.3, 64% of patients were on antiarrhythmic drugs, and 100% were on either beta-blockers or calcium channel blockers. During a mean follow-up of 21.9±15.3 months after the LBBAP and AVN ablation procedure, the average AF or HF hospitalization was 0.4±0.9, and all patients were no longer on any antiarrhythmic drugs, beta-blockers, or calcium channel blockers. There were no cases of lead dislodgement. In patients with elevated PA systolic pressure, successful LBBAP and AVN ablation with good two-year outcomes are achievable.Tabled 1Pre LBBAP and AVN ablation*Post LBBAP and AVN ablation**P-valueAF or HF hospitalizations4.9 ± 5.30.4 ± 0.9P<0.01On antiarrhythmic drugs7 (63.6%)0 (0%)P<0.01On rate control drugs11 (100%)0 (0%)NALead dislodgement-0 (0%)NALead capture threshold, mV-0.7 ± 0.2NAValues are mean ± SD or n (%) *24 months prior to LBBAP and AVN ablation **Average follow-up of 22±15 months after LBBAP and AVN ablation Open table in a new tab

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call